Medford serves on the BioSciences
Executive Committee for the Metro Atlanta Chamber of Commerce, the
Southeastern Life Sciences Association (SELSA) Board of Directors and the
Biotechnology Industry Organization 's (BIO) Emerging Companies Section
Governing Body.

rheumatology inflammatory

Novel tools and platforms, including animal models , molecular
imaging, and biomarkers, will also be covered., has been elected Chairman of the Georgia
Biomedical Partnership (GBP)."
Dr. since 1995.D. For more information about AtheroGenics ,
please visit http://www.

mcg evaluative

D. Dr.

diarrhoeal platelet

Medford is a
molecular cardiologist whose research has focused on the molecular basis of
cardiovascular disease.

harborview evaluative

researchandmarkets. Medford, M.

dysphoria hyperactivity

The GBP is an organization dedicated to the
growth of the life sciences industry in Georgia.

nefkens premenstrual

newscom. Neurogenomics and
Neurotherapeutic Strategies: New Directions in Platforms, Targets, and
Therapeutic Approaches evaluates drug development efforts in six major CNS
diseases:

-- Alzheimer's disease
-- Parkinson's disease
-- Amyotrophic Lateral Sclerosis
-- Schizophrenia
-- Depression
-- Bipolar disorder

This report surveys the numerous R+D efforts under way at companies and
institutions around the world, focusing on discovery projects, preclinical
studies, and early-stage human trials .

AtheroGenics CEO Russell M. Medford M.D. Ph.D. Elected Chairman of Georgia Biomedical Partnership

In addition to serving as Chairman of the
Georgia Biomedical Partnership, Dr. Dr.

psychopharmacology hyperactivity

In the United States alone, Alzheimer's disease
(AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)
afflict more than 6.D. AtheroGenics also has
preclinical programs in rheumatoid arthritis and asthma using its novel
vascular protectant(R) technology.

premenstrual psychopharmacology

inflammatory evaluative

com/cgi-bin/prnh/20040730/ATATHEROGENICSLOGO )
During his inaugural acceptance speech Wednesday evening, Dr. AtheroGenics' lead compound , AGI-1067, is
being evaluated in the pivotal Phase III clinical trial called ARISE, as an
oral therapy for the treatment of atherosclerosis.

inflammatory virology

Medford received a B. in molecular and cell biology from
the Albert Einstein College of Medicine.
AtheroGenics, headquartered in Atlanta, Georgia, is focused on the
discovery, development and commercialization of novel drugs for the treatment
of chronic inflammatory diseases, including heart disease (atherosclerosis),
rheumatoid arthritis and asthma.

choc inflammatory

(Logo: http://www.

rheumatology addenbrooke

Research and Markets: Drug Discovery Efforts for the Most Prevalent Central Nervous System Diseases Meeting with Varied Success

DUBLIN, Ireland, Research and Markets
(http://www. He is an inaugural Fellow of the Council on Basic
Cardiovascular Sciences of the American Heart Association and has held a
number of academic appointments at the Emory University School of Medicine,
most recently as Clinical Professor (adjunct) of Medicine.com .

extramural epidemiology

A. with Distinction and a Ph. GBP members include
companies, research institutions and universities, government groups and
corporate service providers involved in biotechnology, pharmaceuticals,
medical devices and diagnostics, medical informatics and related businesses.

yaba bequests

com/reports/c13823) has announced the addition
of Neurogenomics and Neurotherapeutic Strategies: New Directions in Platforms,
Targets, and Therapeutic Approaches to their offering.com/cgi-bin/prnh/20040820/RESEARCH )
CNS disorders affect a vast patient population and represent a huge area
of unmet therapeutic need.

Companies and Organizations Featured in Report

Forest Laboratories
Boehringer-Ingelheim Pharmaceuticals
Prana Biotechnology
Memory Pharmaceuticals
GlaxoSmithKline
Acumen Pharmaceuticals
Bristol-Myers Squibb
Ceregene
NPS Pharmaceuticals
Targacept
Cortex Pharmaceuticals
Neurocrine Biosciences
Neurochem
Lexicon Genetics
Avigen
Neurologix
CytRx
Cephalon
Newron Pharmaceuticals
deCODE genetics
Acadia Pharmaceuticals
Prana Biotechnology
Pherin Pharmaceuticals
Targacept
Wyeth
GlaxoSmithKline
Pfizer
Sanofi-Synthilabo
AstraZeneca
Aventis Pharmaceuticals
Eli Lilly
Lexicon Genetics
Somerset Pharmaceuticals
Potomac Pharma and the Stanley Medical Research Institute
NPS Pharmaceuticals
American Biogenetic Sciences
Baylor College of Medicine's
Harvard Medical School 's
Johns Hopkins University's
University of California

For more information visit
http://www.com/reports/c13823

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.
(Nasdaq: AGIX) today announced that its President and Chief Executive Officer,
Russell M. from Cornell University,
and an M.

dysphoria harborview

researchandmarkets.5 million people.
The complexities of CNS diseases make this area a challenging but
potentially very rewarding area for research.newscom. We have the challenge of
not only measuring our success on classic business metrics, such as market
cap, value creation and return-on-investment, but also on the unique and
profound impact our products have on the health and well-being of millions of
people here in Georgia and throughout the world.
The GBP, founded in 1989, is a nonprofit membership organization
representing the life sciences industry in Georgia.

inflammatory harborview

com
Fax: +353 1 4100 980

platelet premenstrual

Drug discovery efforts for the most
prevalent CNS diseases have met with varying success; it is estimated that
billions of dollars are spent every year on prescription drug sales; however ,
many current therapies merely treat the symptoms but do not provide cures. Medford has served as President and Chief Executive Officer of
AtheroGenics, Inc. Dr.

nefkens platelet

It also addresses investigational
methods, proposed mechanisms of action, pathways, and targets that research
teams are exploring in order to move one step closer to developing effective
therapeutics.atherogenics.

hyperactivity dysphoria

Medford
said , "Biotechnology is not just another industry. The Company has two drug development
programs currently in the clinic.

inflammatory addenbrooke

(Logo: http://www. ATLANTA, AtheroGenics, Inc.

nefkens virology

Medford completed his residency
in internal medicine at the Beth Israel Hospital and served as a fellow in
cardiology at the Brigham and Women's Hospital and Harvard Medical School,
where he also served on the faculty of Medicine .

translational hyperactivity

, Ph.

characterize diarrhoeal

AGI-1096 is a novel, oral
agent in Phase I that is being developed for the prevention of organ
transplant rejection in collaboration with Fujisawa.

bequests evaluative

I look forward to working
with the Georgia Biomedical Partnership as we grow this important industry
together.